free counter with statistics

Dr Albert Bourla 60: Get ready for boosters every year: Pfizer boss says annual jabs will be needed to maintain ‘very high protection’ as UK orders 114m extra doses to keep country supplied with shots for two more years, Wiki, Bio, Covid-19

Dr Albert Bourla

Dr Albert Bourla Wiki

                          Dr Albert Bourla Biography

Who is Dr Albert Bourla ?

Albert Bourla is a Greek-American veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer’s divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer. Wikipedia


October 21, 1961 (age 60 years), Thessaloniki, Greece


Myriam Alchanati




Aristotle University of Thessaloniki (PhD, DVM)




Chairman and CEO of Pfizer
Albert Bourla

Great news!

Great news! Today the 3 billionth dose of our Pfizer-BioNTech vaccine rolled off the line – meeting our 2021 goal – but we’re not stopping there. 2.2B of these doses have already shipped and the remaining doses will go through our more than 40 quality checks before delivery.


As president and CEO, Albert Bourla leads Pfizer in its purpose: life-changing advancements for patients, with a focus on driving the scientific and commercial innovation necessary to have a transformative impact on human health.

Pfizer’s Chief Operating Officer (COO)

During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding various senior global positions in a variety of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the company’s business strategy, manufacturing, and development functions of Pfizer. global products.

Previously, from February 2016 to December 2017, Albert served as group president of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation and Immunology, Internal Medicine, Oncology, Rare Diseases and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions to increase patient access, demonstrate the value of Pfizer medicines, and ensure broader business model innovation.

From January 2014 to January 2016, Albert served as president of Pfizer’s global vaccine, oncology and consumer health business group, where he was instrumental in building a strong and competitive position in oncology and expanding of the company’s leadership in vaccines.

Albert was president and general manager of Pfizer’s Established Products business from 2010 to 2013, and led the development and implementation of strategies and tactics related to Pfizer’s portfolio of non-patent products (including legacy brands and generics).

Pharmaceutical company worked

Last year, teams at the pharmaceutical company worked at record speed to develop and test an mRNA vaccine, which uses the information in a person’s cells to produce a protein that triggers an immune response.

“It was a time when the world was really scared. It was a time when we were all living things that we had never lived before, we never thought we would live, “Pfizer President and CEO Dr. Albert Bourla told the audience at the Fortune CEO Initiative on Monday. in Washington, DC

Saving lives and ending the confinements were great motivators, of course. But Bourla attributes it to certain strategic decisions made by the company that helped it move more quickly toward a vaccine.


The CEO says Pfizer focused on breaking internal and external bureaucracy that would otherwise slow down its scientists. The drugmaker didn’t take money from the government, because Bourla said Pfizer scientists would have to waste time in committee meetings detailing how they were spending public funds.

Bourla also made sure to join teams so decisions could be made faster.

In organizations, “because of silos, it’s very difficult to make decisions,” she said. Having the CEO or another executive in the meetings helped speed up the Pfizer process.

The Pfizer team also operated with a sense of purpose, which she said was framed by the question: “If it’s not us, then who?”

“It was a time when people needed to rise to the occasion no matter what,” Bourla said.

A year after the results of the first vaccine trial were published, Pfizer’s impact has been undeniable. In addition to the vaccine, Pfizer also has an antiviral pill.

“If we didn’t have a vibrant life sciences industry, we wouldn’t be here today,” said the CEO.

Show More

Related Articles

Leave a Reply

Your email address will not be published.